Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment
by
Menko, Fred H.
, Middelton, Lindsay A.
, Maher, Eamonn R.
, Tomlinson, Ian
, Aittomäki, Kristiina
, Schmidt, Laura S.
, Linehan, W. Marston
, Richard, Stéphane
in
Biomedical and Life Sciences
/ Biomedicine
/ Cancer Research
/ Carcinoma, Renal Cell - diagnosis
/ Carcinoma, Renal Cell - genetics
/ Early Detection of Cancer - methods
/ Epidemiology
/ Female
/ Human Genetics
/ Humans
/ Kidney Neoplasms - diagnosis
/ Kidney Neoplasms - genetics
/ Leiomyomatosis - complications
/ Male
/ Middle Aged
/ Neoplastic Syndromes, Hereditary
/ Original Article
/ Skin Neoplasms - complications
/ Uterine Neoplasms - complications
2014
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment
by
Menko, Fred H.
, Middelton, Lindsay A.
, Maher, Eamonn R.
, Tomlinson, Ian
, Aittomäki, Kristiina
, Schmidt, Laura S.
, Linehan, W. Marston
, Richard, Stéphane
in
Biomedical and Life Sciences
/ Biomedicine
/ Cancer Research
/ Carcinoma, Renal Cell - diagnosis
/ Carcinoma, Renal Cell - genetics
/ Early Detection of Cancer - methods
/ Epidemiology
/ Female
/ Human Genetics
/ Humans
/ Kidney Neoplasms - diagnosis
/ Kidney Neoplasms - genetics
/ Leiomyomatosis - complications
/ Male
/ Middle Aged
/ Neoplastic Syndromes, Hereditary
/ Original Article
/ Skin Neoplasms - complications
/ Uterine Neoplasms - complications
2014
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment
by
Menko, Fred H.
, Middelton, Lindsay A.
, Maher, Eamonn R.
, Tomlinson, Ian
, Aittomäki, Kristiina
, Schmidt, Laura S.
, Linehan, W. Marston
, Richard, Stéphane
in
Biomedical and Life Sciences
/ Biomedicine
/ Cancer Research
/ Carcinoma, Renal Cell - diagnosis
/ Carcinoma, Renal Cell - genetics
/ Early Detection of Cancer - methods
/ Epidemiology
/ Female
/ Human Genetics
/ Humans
/ Kidney Neoplasms - diagnosis
/ Kidney Neoplasms - genetics
/ Leiomyomatosis - complications
/ Male
/ Middle Aged
/ Neoplastic Syndromes, Hereditary
/ Original Article
/ Skin Neoplasms - complications
/ Uterine Neoplasms - complications
2014
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment
Journal Article
Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment
2014
Request Book From Autostore
and Choose the Collection Method
Overview
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant condition in which susceptible individuals are at risk for the development of cutaneous leiomyomas, early onset multiple uterine leiomyomas and an aggressive form of type 2 papillary renal cell cancer. HLRCC is caused by germline mutations in the
fumarate hydratase
(
FH
) gene which inactivate the enzyme and alters the function of the tricarboxylic acid (Krebs) cycle. Issues surrounding surveillance and treatment for HLRCC-associated renal cell cancer were considered as part of a recent international symposium on HLRCC. The management protocol proposed in this article is based on a literature review and a consensus meeting. The lifetime renal cancer risk for
FH
mutation carriers is estimated to be 15 %. In view of the potential for early onset of RCC in HLRCC, periodic renal imaging and, when available, predictive testing for a
FH
mutation is recommended from 8 to 10 years of age. However, the small risk of renal cell cancer in the 10–20 years age range and the potential drawbacks of screening should be carefully discussed on an individual basis. Surveillance preferably consists of annual abdominal MRI. Treatment of renal tumours should be prompt and generally consist of wide-margin surgical excision and consideration of retroperitoneal lymph node dissection. The choice for systemic treatment in metastatic disease should, if possible, be part of a clinical trial. Screening procedures in HLRCC families should preferably be evaluated in large cohorts of families.
Publisher
Springer Netherlands,Springer Nature B.V
This website uses cookies to ensure you get the best experience on our website.